Adverse Effects | Topics

A complete response letter has been issued to BeyondSpring Pharmaceuticals for plinabulin plus granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia.

A phase 2 trial examining the use of small molecule immunomodulator EC-18 in patients with head and neck cancer experiencing chemoradiation-induced oral mucositis met its primary and secondary end points.

The FDA approved the first and only erythroid maturation agent for the treatment of anemia in patients with lower-risk myelodysplastic syndromes.

The agency approved the first and only FDA-approved erythroid maturation agent to treat anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.

A new study has revealed that the amount of iron in the blood affects the amount of the Scribble protein, which appears to control receptors that create new red blood cells.

Using a super computer, a team at Brown University has created a model of sickle cell anemia, devising a method that could help researchers assess and evaluate treatments to combat sickle cell disease.